Stem Cell Market Report 2025

This Stem Cell market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The stem cell market size has grown strongly in recent years. It will grow from $15.34 billion in 2024 to $16.85 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to advancements in regenerative medicine, growing prevalence of chronic diseases, research and development initiatives, increasing aging population, rising awareness and acceptance.

The stem cell market size is expected to see rapid growth in the next few years. It will grow to $25.92 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to expanding applications in oncology, innovations in personalized medicine, government support and funding, biotechnology collaborations and partnerships, clinical trials and regulatory approvals. Major trends in the forecast period include commercialization of stem cell therapies, application of CRISPR technology, regulatory framework development, investments in stem cell research, focus on exosome therapeutics.

The rising prevalence of chronic diseases worldwide is fueling growth in the stem cell market. Stem cell therapy involves using stem cells to treat or prevent various diseases and conditions. While bone marrow transplants are the most widely utilized form of stem cell therapy, treatments derived from umbilical cord blood are also becoming increasingly common. Currently, the transplantation of blood stem cells is a prominent application, particularly for treating blood and immune system disorders or for restoring the blood system following cancer treatments. For instance, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK are affected by allergies, making it the most commonly reported chronic health condition in 2022. Projections suggest that by 2026, half of Europe’s population will experience at least one allergy. Therefore, the increasing prevalence of chronic diseases worldwide is driving the growth of the stem cell market.

The growth of the stem cell market is further fueled by the increasing demand for personalized medicine. Personalized medicine tailors medical treatment to an individual's unique genetic makeup, providing more precise and effective healthcare interventions. Stem cells, in the context of personalized medicine, offer the potential for regenerating and replacing damaged tissues, allowing for treatments tailored to individual patients. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the rising demand for personalized medicine contributes to the growth of the stem cell market.

Companies operating in the stem cell therapeutics market are concentrating on advancing technologies, such as Induced Pluripotent Stem Cells (IPSC), to enhance the effectiveness of stem cell therapies. IPSCs are derived from blood or skin cells that undergo reprogramming to achieve an embryonic-such as pluripotent state. This process involves the introduction of genes essential for maintaining key properties and promoting the growth of an unlimited source of any human cell type required for stem cell therapeutic purposes. Importantly, IPSCs are not derived from human embryos, addressing bioethical concerns and facilitating easier access to federal funding and support. An illustrative example is the Japanese company Oksara, which inaugurated a medicine center producing cells derived from IPSCs. Similarly, Takar Bio introduced human iPSC-derived Beta Cells, known as Cellartis, designed for disease modeling and drug discovery.

Major companies in the stem cell market are also prioritizing the development of automated stem cell analysis systems to gain a competitive advantage. These systems streamline the assessment of stem cell characteristics and viability, enhancing research and clinical applications with increased efficiency and precision. For instance, in May 2022, Beckman Coulter Inc., a US-based healthcare company, launched the AQUIOS STEM System, a solution specifically engineered for stem cell analysis. This system offers full automation, reducing hands-on time by 95% and minimizing error-prone tasks by 87.5%. Combining the automation capabilities of the AQUIOS CL with a stem cell enumeration solution, it can be customized to meet diverse requirements.

In April 2023, STEMCELL Technologies, a leading biotechnology firm based in Canada, acquired SQZ Biotechnologies Company for an undisclosed amount. This acquisition aims to strengthen STEMCELL's capabilities in delivering cell therapies by leveraging SQZ's innovative mechanoporation technology, which enables the introduction of therapeutic cargo into cells without the use of electricity. SQZ Biotechnologies, located in the United States, specializes in developing advanced methods for delivering therapeutic cargo into cells through this mechanoporation process. SQZ Biotechnologies Co. is recognized as a clinical-stage biotechnology company based in the U.S.

Stem cells, whether autologous or allogenic, possess the ability to differentiate into various cell types both in vivo and in vitro, making them valuable in the medical treatment of injuries and organ damage.

The primary product categories of stem cells include adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and others. Adult stem cells represent a rare cell population in the body during the majority of postnatal life, capable of giving rise to a limited number of mature cell types that contribute to the formation of the tissue in which they are located. These stem cells can be derived from autologous or allogeneic sources and find applications in diverse areas such as regenerative medicine, drug discovery, and development.

The stem cell market research report is one of a series of new reports that provides stem cell market statistics, including stem cell market industry global market size, regional shares, competitors with a stem cell market share, detailed stem cell market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell market industry. This stem cell market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the stem cell market include Danaher Corporation, Cryo-Cell International Inc., Daiichi Sankyo Company Limited, Lonza Group Ltd, PerkinElmer Inc., CellGenix GmbH, China Cord Blood Corporation, Organogenesis Holdings Inc., LifeCell International, Cord Blood America Inc., StemCyte Inc., Cryoviva India, Cordlife Group Limited, Thermo Fisher Scientific Inc., CordVida, Cryo Stemcell Inc., Pluristem Therapeutics Inc., Mesoblast Limited, Americord Registry LLC, Smart Cells International, Athersys Inc., ReeLabs Pvt. Ltd., Cytori Therapeutics Inc., Esperite N.V., Stemade Biotech, ViaCord, Aldagen Inc, Isto Biologics, Brainstorm Cell Therapeutics Inc.

North America was the largest region in the stem cell market in 2024. Western Europe was the second largest region in the global stem cell market share. The regions covered in the stem cell market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.